Company profile: AutoGenomics
1.1 - Company Overview
Company description
- Provider of automated microarray-based multiplex molecular diagnostic platforms and genetic testing tools, including INFINITI System, INFINITI PLUS Analyzer, INFINITI High Throughput System, proprietary BioFilmChip microarrays, and assays such as AvertD for opioid use disorder risk and Factor II-V Leiden for thrombophilia, for disease signature assessment in women's health, cancer and personalized medicine.
Products and services
- BioFilmChip Microarrays: Custom-engineered proprietary microarrays that multiplex and configure novel genetic biomarkers to assess disease signatures in women's health, cancer, and personalized medicine using the INFINITI platform
- INFINITI High Throughput System (HTS): Enterprise-scale system engineered for high-volume processing of INFINITI assays, suitable for large-scale laboratory operations performing multiplex genetic testing
- INFINITI System: Laboratory-grade automated platform that processes BioFilmChip microarrays for genetic analysis, boosting productivity and workflow while enabling microarray-based multiplexing in molecular diagnostics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AutoGenomics
Foresight Diagnostics
HQ: United States
Website
- Description: Provider of liquid biopsy-based cancer detection and monitoring solutions leveraging patient-specific phased variants, including Foresight CLARITY MRD assays for lymphoma and solid tumors; the PhasED-Seq high-sensitivity ctDNA test; MRD-driven clinical trials; a ctDNA research assay to quantify and monitor disease burden; and customizable SNV and CNV genotyping.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Foresight Diagnostics company profile →
Prime Medicine
HQ: United States
Website
- Description: Provider of gene editing technologies and therapies utilizing Prime Editing to modify genetic sequences to treat a wide range of diseases. Offerings include Prime Editors for precise edits across tissues and cell types, Dual Flap Prime Editing for broader edits, PASSIGE for inserting large gene-sized sequences, and Prime-Edited Cell Therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prime Medicine company profile →
Resolution Bioscience
HQ: United States
Website
- Description: Provider of next-generation liquid biopsy cancer diagnostics using NGS to interrogate cell-free DNA from blood. Offerings include the ctDx Platform; ctDx FIRST, an FDA-approved NGS assay for comprehensive genomic profiling of 109 genes and detection of KRAS G12C in NSCLC; ctDx Lung for real-time NSCLC genotype assessment; custom liquid-biopsy panels for clinical trials and companion diagnostics; and TCR profiling for immuno-oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Resolution Bioscience company profile →
Cellmark
HQ: United Kingdom
Website
- Description: Provider of DNA testing services, specializing in DNA analysis, paternity testing, and hair drug and alcohol testing, among others.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellmark company profile →
OncoMethylome
HQ: Belgium
Website
- Description: Provider of molecular diagnostics focused on developing gene methylation tests for early detection of cancer and personalized treatment decisions, offering novel, accurate, and informative diagnostic tools for treating physicians.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoMethylome company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AutoGenomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AutoGenomics
2.2 - Growth funds investing in similar companies to AutoGenomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AutoGenomics
4.2 - Public trading comparable groups for AutoGenomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →